Literature DB >> 1903313

Intranasal fractionated administration of desamino-D-arginine vasopressin (DDAVP) in patients with von Willebrand's disease.

B Garicochea, E A D'Amico, S P Bydlowski, D A Chamone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1903313     DOI： 10.1007/bf01714906

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  5 in total

1.  The treatment of haemorrhage in von Willebrand's disease and the blood level of factor VIII (AHG).

Authors:  R BIGGS; J M MATTHEWS
Journal:  Br J Haematol       Date:  1963-04       Impact factor: 6.998

2.  Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I.

Authors:  S Lethagen; A S Harris; I M Nilsson
Journal:  Blut       Date:  1990-03

3.  Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).

Authors:  M Köhler; P Hellstern; C Miyashita; G von Blohn; E Wenzel
Journal:  Thromb Haemost       Date:  1986-02-28       Impact factor: 5.249

Review 4.  Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders.

Authors:  P M Mannucci
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

Review 5.  Desmopressin: a nontransfusional hemostatic agent.

Authors:  P M Mannucci
Journal:  Annu Rev Med       Date:  1990       Impact factor: 13.739
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.